Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach

Biomarkers predicting treatment response to the monoclonal antibody cetuximab in locally advanced head and neck squamous cell carcinomas (LAHNSCC) are lacking. We hypothesize that tumor accessibility is an important factor in treatment success of the EGFR targeting drug. We quantified uptake of cetu...

Descripción completa

Detalles Bibliográficos
Autores principales: Even, Aniek J.G., Hamming-Vrieze, Olga, van Elmpt, Wouter, Winnepenninckx, Véronique J.L., Heukelom, Jolien, Tesselaar, Margot E.T., Vogel, Wouter V., Hoeben, Ann, Zegers, Catharina M.L., Vugts, Daniëlle J., van Dongen, Guus A.M.S., Bartelink, Harry, Mottaghy, Felix M., Hoebers, Frank, Lambin, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354801/
https://www.ncbi.nlm.nih.gov/pubmed/27965472
http://dx.doi.org/10.18632/oncotarget.13910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354801/
https://www.ncbi.nlm.nih.gov/pubmed/27965472
http://dx.doi.org/10.18632/oncotarget.13910

Ejemplares similares